Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

被引：2

作者：

Vij, Ravi ^{[1
]}

Savona, Michael ^{[2
]}

Siegel, David S. ^{[3
]}

Kaufman, Jonathan L. ^{[4
]}

Badros, Ashraf ^{[5
]}

Ghobrial, Irene M. ^{[6
]}

Paner, Agne ^{[7
]}

Jagannath, Sundar ^{[8
]}

Jakubowiak, Andrzej ^{[9
]}

Mikhael, Joseph R. ^{[10
]}

Kapoor, Prashant ^{[11
]}

Neuman, Linda L. ^{[12
]}

Lee, Ju RueyJiuan ^{[13
]}

Berdeja, Jesus G. ^{[14
]}

机构：

[1] Washington Univ, Sch Med, St Louis, MO USA

[2] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA

[3] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Univ Maryland, Baltimore, MD 21201 USA

[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[8] Mt Sinai Hosp, New York, NY 10029 USA

[9] Univ Chicago Med, Chicago, IL USA

[10] Mayo Clin Arizona, Scottsdale, AZ USA

[11] Mayo Clin, Rochester, MN USA

[12] Onyx Pharmaceut Inc, Redwood City, CA USA

[13] Onyx Pharmaceut Inc, San Francisco, CA USA

[14] Sarah Cannon Res Inst, Nashville, TN USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Siegel, David S.
Oriol, Albert
Rajnics, Peter
Minarik, Jiri
Hungria, Vania
Lee, Jae Hoon
Song, Kevin
Obreja, Mihaela
Aggarwal, Sanjay
Hajek, Roman
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E142 - E142
[22] Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.
Krebs, Matthew
Johnson, Melissa Lynne
Cho, Byoung Chul
Park, Keunchil
Haddish-Berhane, Nahor
Zemlickis, Donna
Mitselos, Anna
Meacle, Francis
Knoblauch, Roland Elmar
Hellemans, Peter
Minchom, Anna Rachel
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Clemens, Pamela L.
Xu, Steven
Luo, Melody
Chari, Ajai
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
San-Miguel, Jesus F.
Sun, X. Yu-Nien
Farnsworth, Andrew
Masterson, Tara
Hellemans, Peter
Qi, Ming
Nahi, Hareth
BLOOD, 2018, 132
[24] AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE AND WITH BACKBONE REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA
Mateos, M. V.
Moreau, P.
Comenzo, R.
Blade, J.
Benboubker, L.
de la Rubia, J.
Facon, T.
Fay, J.
Qin, X.
Masterson, T.
Schecter, J.
Ahmadi, T.
San-Miguel, J.
HAEMATOLOGICA, 2015, 100 : 84 - 84
[25] A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; Prelininary results.
Richardson, P
Jagannath, S
Hussein, M
Berenson, J
Singhal, S
Irwin, D
Williams, SF
Bensinger, W
Badros, AZ
Vescio, R
Kenvin, L
Yu, ZN
Olesnyckyj, M
Faleck, H
Zeldis, J
Knight, R
Anderson, KC
BLOOD, 2005, 106 (11) : 449A - 449A
[26] Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study
Lonial, Sagar
San-Miguel, Jesus F.
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
Oriol, Albert
Arnulf, Bertrand
Chari, Ajai
Pineiro, Luis
Wu, Kaida
Wang, Jianping
Doshi, Parul
Schecter, Jordan
Moreau, Philippe
BLOOD, 2017, 130
[27] Updated Results of Bortezomib-Naive Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM)
Wang, Luhua
Siege, David
Kaufman, Jonathan L.
Stewart, A. Keith
Jakubowiak, Andrzej J.
Alsina, Melissa
Kukreti, Vishal
Bahlis, Nizar J.
McDonagh, Kevin T.
Belch, Andrew
Sebag, Michael
Gabrail, Nashat
Le, Mai H.
Bennett, Mark K.
Kunkel, Lori
Kauffman, Michael
Orlowski, Robert Z.
Vij, Ravi
BLOOD, 2009, 114 (22) : 127 - 128
[28] Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
San-Miguel, Jesus
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Liu, Kevin
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Luo, Man
Farnsworth, Andrew
Nahi, Hareth
Chari, Ajai
HAEMATOLOGICA, 2021, 106 (06) : 1725 - 1732
[29] PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
Siegel, David
Wang, Luhua
Orlowski, Robert Z.
Kaufman, Jonathan L.
Stewart, A. Keith
Kukreti, Vishal
Alsina, Melissa
Jakubowiak, Andrzej J.
Jagannath, Sundar
McDonagh, Kevin T.
Belch, Andrew
Bahlis, Nizar J.
Shustik, Chaim
Le, Mai H.
Kunkel, Lori
Bennett, Mark K.
Kauffman, Michael
Vij, Ravi
BLOOD, 2009, 114 (22) : 128 - 128
[30] A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
Walling, Jackie M.
Matusow, Bernice
Nichols, Christine
Singh, Parmveer
Inokuchi, Kerry
Bollag, Gideon
BLOOD, 2024, 144 : 7022 - 7023

← 1 2 3 4 5 →